Disposable Biopharmaceutical Processes–Myth or Reality? - - BioPharm International

ADVERTISEMENT

Disposable Biopharmaceutical Processes–Myth or Reality?


BioPharm International


Keith DiBlasi is the manager of technical services, Sartorius North America, Inc., Edgewood, NY. Maik W. Jornitz is the group vice president of bioprocess biosystems. Uwe Gottschalk, PhD, is the group vice president of purification technologies, Sartorius AG, Goettingen, Germany. Paul M. Priebe is head of product management process, Edgewood, NY.

References

1. Sinclair A, Monge M. Quantitative economic evaluation of single use disposables in bioprocessing. Pharmaceutical Eng. 2002;22: 20–34.

2. Prashad M, Tarrach K. Depth filtration aspects for the clarification of CHO cell derived biopharmaceutical feed streams. FISE. 2006;9:28–30.

3. Mora J, Sinclair A, Delmdahl N, Gottschalk U. Disposable membrane chromatography: performance analysis and economic cost model. BioProcess Int. 2006;4:38–43.

4. Zhou JX, Tressel T. Membrane chromatography as a robust purification system for large scale antibody production. BioProcess Int.2005; 3: 32–37.

5. Zhou JX, Tressel T. Basic concepts in Q membrane chromatography for large-scale antibody production. Biotechnol Progr. 2006;22:341–9.

6. Ransohoff T. Disposable Chromatography: Current Capabilities and Future Possibilities. BPD North Carolina Biotechnology Center, 2004 Nov 18.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here